AbbVie unveiled that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson's disease. The application relies on data from the TEMPO clinical trail program, which tested the safety, tolerability, and effectivene... https://www.coherentmarketinsights.com/news/abbvie-submitted-new-drug-application-to-the-us-fda-for-tavapadon-1600